Stockpolly
Search
SKYE · NASDAQ · Biotechnology

Skye Bioscience (SKYE)

Developing an investigational peripheral cannabinoid-receptor antibody for obesity.

$1.89
Pre-market+0.04 (+2.16%)
At close$1.85(+2.78%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
25468511121813151311
Research & development12245871491184
224455544354
General & administrative224455544354
Other expenses21000−5−2000003
Operating income−25−4−6−8−5−11−12−18−13−15−13−11
001111111000
Interest income000111110000
Interest expense00000—000000
Other non-operating income00−2−1−1−1−1−1−1000
Income before tax−25−4−5−8−4−10−11−18−13−14−13−11
Income tax expense000000000000
Net income from continuing operations−25−4−5−8−4−10−11−18−13−14−13−11
Net income−25−4−5−8−4−10−11−18−13−14−13−11
EPS, basic−$3.17−$2.88−$1.44−$1.60−$0.80−$1.92−$2.24−$3.52−$2.56−$2.88−$2.56−$2.16
EPS, diluted−$3.17−$2.88−$1.44−$1.60−$0.80−$1.92−$2.24−$3.52−$2.56−$2.88−$2.56−$2.16
Weighted average shares, basic824555555555
Weighted average shares, diluted824555555555
EBITDA−25−4−5−7−4−10−11−17−13−14−12−11
Depreciation & amortization000000000000
EBIT−25−4−5−7−4−10−11−18−13−14−13−11